Cargando…

Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes

BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynders, Veerle, Loitsch, Stefan, Steinhauer, Constanze, Wagner, Thomas, Steinhilber, Dieter, Bargon, Joachim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562413/
https://www.ncbi.nlm.nih.gov/pubmed/16875506
http://dx.doi.org/10.1186/1465-9921-7-104
_version_ 1782129496968658944
author Reynders, Veerle
Loitsch, Stefan
Steinhauer, Constanze
Wagner, Thomas
Steinhilber, Dieter
Bargon, Joachim
author_facet Reynders, Veerle
Loitsch, Stefan
Steinhauer, Constanze
Wagner, Thomas
Steinhilber, Dieter
Bargon, Joachim
author_sort Reynders, Veerle
collection PubMed
description BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ mRNA levels were measured in peripheral blood cells of CF patients and healthy subjects via RT-PCR. PPARα protein expression and subcellular localization was determined via western blot and immunofluorescence, respectively. The activity of PPARα was analyzed by gel shift assay. RESULTS: In lymphocytes, the expression of PPARα mRNA, but not of PPARβ, was reduced (-37%; p < 0.002) in CF patients compared with healthy persons and was therefore further analyzed. A similar reduction of PPARα was observed at protein level (-26%; p < 0.05). The transcription factor was mainly expressed in the cytosol of lymphocytes, with low expression in the nucleus. Moreover, DNA binding activity of the transcription factor was 36% less in lymphocytes of patients (p < 0.01). For PPARα and PPARβ mRNA expression in monocytes and neutrophils, no significant differences were observed between CF patients and healthy persons. In all cells, PPARγ mRNA levels were below the detection limit. CONCLUSION: Lymphocytes are important regulators of the inflammatory response by releasing cytokines and antibodies. The diminished lymphocytic expression and activity of PPARα may therefore contribute to the inflammatory processes that are observed in CF.
format Text
id pubmed-1562413
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15624132006-09-08 Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes Reynders, Veerle Loitsch, Stefan Steinhauer, Constanze Wagner, Thomas Steinhilber, Dieter Bargon, Joachim Respir Res Research BACKGROUND: PPARs exhibit anti-inflammatory capacities and are potential modulators of the inflammatory response. We hypothesized that their expression and/or function may be altered in cystic fibrosis (CF), a disorder characterized by an excessive host inflammatory response. METHODS: PPARα, β and γ mRNA levels were measured in peripheral blood cells of CF patients and healthy subjects via RT-PCR. PPARα protein expression and subcellular localization was determined via western blot and immunofluorescence, respectively. The activity of PPARα was analyzed by gel shift assay. RESULTS: In lymphocytes, the expression of PPARα mRNA, but not of PPARβ, was reduced (-37%; p < 0.002) in CF patients compared with healthy persons and was therefore further analyzed. A similar reduction of PPARα was observed at protein level (-26%; p < 0.05). The transcription factor was mainly expressed in the cytosol of lymphocytes, with low expression in the nucleus. Moreover, DNA binding activity of the transcription factor was 36% less in lymphocytes of patients (p < 0.01). For PPARα and PPARβ mRNA expression in monocytes and neutrophils, no significant differences were observed between CF patients and healthy persons. In all cells, PPARγ mRNA levels were below the detection limit. CONCLUSION: Lymphocytes are important regulators of the inflammatory response by releasing cytokines and antibodies. The diminished lymphocytic expression and activity of PPARα may therefore contribute to the inflammatory processes that are observed in CF. BioMed Central 2006 2006-07-30 /pmc/articles/PMC1562413/ /pubmed/16875506 http://dx.doi.org/10.1186/1465-9921-7-104 Text en Copyright © 2006 Reynders et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Reynders, Veerle
Loitsch, Stefan
Steinhauer, Constanze
Wagner, Thomas
Steinhilber, Dieter
Bargon, Joachim
Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title_full Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title_fullStr Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title_full_unstemmed Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title_short Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
title_sort peroxisome proliferator-activated receptor α (pparα) down-regulation in cystic fibrosis lymphocytes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562413/
https://www.ncbi.nlm.nih.gov/pubmed/16875506
http://dx.doi.org/10.1186/1465-9921-7-104
work_keys_str_mv AT reyndersveerle peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes
AT loitschstefan peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes
AT steinhauerconstanze peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes
AT wagnerthomas peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes
AT steinhilberdieter peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes
AT bargonjoachim peroxisomeproliferatoractivatedreceptorapparadownregulationincysticfibrosislymphocytes